These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 27519353)

  • 1. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases.
    Baratti D; Kusamura S; Iusco D; Gimondi S; Pietrantonio F; Milione M; Guaglio M; Bonomi S; Grassi A; Virzì S; Leo E; Deraco M
    Ann Surg Oncol; 2017 Jan; 24(1):167-175. PubMed ID: 27519353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.
    Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S
    Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study.
    Goéré D; Glehen O; Quenet F; Guilloit JM; Bereder JM; Lorimier G; Thibaudeau E; Ghouti L; Pinto A; Tuech JJ; Kianmanesh R; Carretier M; Marchal F; Arvieux C; Brigand C; Meeus P; Rat P; Durand-Fontanier S; Mariani P; Lakkis Z; Loi V; Pirro N; Sabbagh C; Texier M; Elias D;
    Lancet Oncol; 2020 Sep; 21(9):1147-1154. PubMed ID: 32717180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
    Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
    BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
    Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
    Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies.
    de Cuba EM; Kwakman R; Knol DL; Bonjer HJ; Meijer GA; Te Velde EA
    Cancer Treat Rev; 2013 Jun; 39(4):321-7. PubMed ID: 23244778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
    Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
    Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
    Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of colorectal cancer patients at high risk of peritoneal metastases.
    Shariff U; Seretis C; Youssef H
    J BUON; 2015 May; 20 Suppl 1():S71-9. PubMed ID: 26051336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatectomy for metachronous colorectal liver metastases following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases: a report of three cases.
    Ito K; Takemura N; Inagaki F; Mihara F; Kurokawa T; Gohda Y; Kiyomatsu T; Yano H; Kokudo N
    World J Surg Oncol; 2019 Jun; 17(1):99. PubMed ID: 31196097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC.
    Sluiter NR; Rovers KP; Salhi Y; Vlek SL; Coupé VMH; Verheul HMW; Kazemier G; de Hingh IHJT; Tuynman JB
    Ann Surg Oncol; 2018 Aug; 25(8):2347-2356. PubMed ID: 29855834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory bowel disease drastically affects the prognosis of patients treated for peritoneal metastases with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study.
    Hammoudi N; Eveno C; Lambert J; Maillet M; Glehen O; Goere D; Lourenco N; Allez M; Aparicio T; Pocard M; Gornet JM;
    Eur J Surg Oncol; 2018 Jun; 44(6):799-804. PubMed ID: 29650418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases.
    Virzì S; Iusco D; Baratti D; Bonomi S; Grassi A; Kusamura S; Deraco M
    Tumori; 2013; 99(5):589-95. PubMed ID: 24362862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
    Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
    Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial.
    Klaver CE; Musters GD; Bemelman WA; Punt CJ; Verwaal VJ; Dijkgraaf MG; Aalbers AG; van der Bilt JD; Boerma D; Bremers AJ; Burger JW; Buskens CJ; Evers P; van Ginkel RJ; van Grevenstein WM; Hemmer PH; de Hingh IH; Lammers LA; van Leeuwen BL; Meijerink WJ; Nienhuijs SW; Pon J; Radema SA; van Ramshorst B; Snaebjornsson P; Tuynman JB; Te Velde EA; Wiezer MJ; de Wilt JH; Tanis PJ
    BMC Cancer; 2015 May; 15():428. PubMed ID: 26003804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
    Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peritoneal carcinomatosis with synchronous liver metastases from colorectal cancer: Who will benefit from complete cytoreductive surgery?
    Delhorme JB; Dupont-Kazma L; Addeo P; Lefebvre F; Triki E; Romain B; Meyer N; Bachellier P; Rohr S; Brigand C
    Int J Surg; 2016 Jan; 25():98-105. PubMed ID: 26607853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients.
    Baratti D; Kusamura S; Iusco D; Bonomi S; Grassi A; Virzì S; Leo E; Deraco M
    Dis Colon Rectum; 2014 Jul; 57(7):858-68. PubMed ID: 24901687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged perioperative thoracic epidural analgesia may improve survival after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A comparative study.
    Lorimier G; Seegers V; Coudert M; Dupoiron D; Thibaudeau E; Pouplin L; Lebrec N; Dubois PY; Dumont F; Guérin-Meyer V; Capitain O; Campone M; Wernert R
    Eur J Surg Oncol; 2018 Nov; 44(11):1824-1831. PubMed ID: 30213715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Devilee RA; Simkens GA; van Oudheusden TR; Rutten HJ; Creemers GJ; Ten Tije AJ; de Hingh IH
    Ann Surg Oncol; 2016 Sep; 23(9):2841-8. PubMed ID: 27044447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.